


**Brilliant Violet 421™ anti-mouse/human CD45R/B220**

**Catalog # / Size:** 1116200 / 500 µl  
1116195 / 125 µl  
  
1116255 / 50 µg  
**Clone:** RA3-6B2  
**Isotype:** Rat IgG2a, κ  
**Immunogen:** Abelson murine leukemia virus-induced pre-B tumor cells  
**Reactivity:** Human  
**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.  
**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).  
**Concentration:** NULL




C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry  
**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. For immunohistochemistry, a concentration range of 2.5 - 10 microg per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly



C57BL/6 mouse frozen spleen sections were fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS plus 5% rat/mouse serum for 30 minutes at room temperature. Then the section was stained with 1.25 microg/ml of an

prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>1</sup>, *in vitro* and *in vivo* modulation of B cell responses<sup>2-4</sup>, and immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections<sup>5,6</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 103216).

**Application References:**

1. Coffman RL. 1982. *Immunol. Rev.* 69:5. (IP)
2. George A, *et al.* 1994. *J. Immunol.* 152:1014. (Activ)
3. Asensi V, *et al.* 1989. *Immunology* 68:204. (Activ)
4. Domiati-Saad R, *et al.* 1993. *J. Immunol.* 151:5936. (Activ)
5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Monteith CE, *et al.* 1996. *Can. J. Vet. Res.* 60:193. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Chang C L-T, *et al.* 2007. *J. Immunol.* 178:6984.
9. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
10. Lang GL, *et al.* 2008. *Blood* 111:2158. [PubMed](#)
11. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
12. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
13. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)

---

**Description:** CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-*Fas*<sup>lpr</sup> and MRL-*Fas*<sup>gld</sup> mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

**Antigen References:**

1. Barclay A, *et al.* 1997. *The Leukocyte Antigen FactsBook* Academic Press.
2. Trowbridge IS, *et al.* 1993. *Annu. Rev. Immunol.* 12:85.
3. Kishihara K, *et al.* 1993. *Cell* 74:143.
4. Pulido R, <